Connor Clark & Lunn Investment Management Ltd. Has $5.44 Million Stake in Enovis Co. (NYSE:ENOV)

Connor Clark & Lunn Investment Management Ltd. lessened its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 20.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 126,440 shares of the company's stock after selling 31,643 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.23% of Enovis worth $5,443,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Diamond Hill Capital Management Inc. boosted its holdings in Enovis by 7.8% during the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company's stock valued at $129,352,000 after purchasing an additional 218,660 shares in the last quarter. Royce & Associates LP boosted its stake in Enovis by 16.8% in the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company's stock valued at $103,479,000 after buying an additional 346,317 shares in the last quarter. American Century Companies Inc. grew its position in Enovis by 78.6% in the second quarter. American Century Companies Inc. now owns 1,511,871 shares of the company's stock valued at $68,337,000 after acquiring an additional 665,208 shares during the period. River Road Asset Management LLC bought a new position in shares of Enovis during the third quarter valued at $51,341,000. Finally, Magnetar Financial LLC boosted its stake in shares of Enovis by 66.7% in the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company's stock valued at $49,937,000 after purchasing an additional 442,051 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ENOV shares. JPMorgan Chase & Co. cut their price target on shares of Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a report on Thursday, August 8th. Needham & Company LLC reiterated a "buy" rating and issued a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th. JMP Securities assumed coverage on Enovis in a research report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price target on the stock. Finally, Evercore ISI cut their price objective on Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, Enovis currently has a consensus rating of "Moderate Buy" and an average price target of $67.00.

Enovis Trading Up 1.1 %

NYSE:ENOV traded up $0.50 during trading hours on Friday, hitting $46.67. 604,677 shares of the stock were exchanged, compared to its average volume of 741,996. The company's 50 day moving average is $42.70 and its two-hundred day moving average is $45.01. The company has a market capitalization of $2.61 billion, a P/E ratio of -21.31 and a beta of 1.91. Enovis Co. has a twelve month low of $38.27 and a twelve month high of $65.03. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.11. The business had revenue of $505.22 million for the quarter, compared to analysts' expectations of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm's quarterly revenue was up 21.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.56 earnings per share. On average, sell-side analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.